The Merck Group Website
The Merck Group Website

Neurodegenerative Diseases

Neurodegenerative Diseases
Neurodegenerative Diseases

Focus on personalized solutions for unmet medical needs

Merck Serono has a long-term commitment to developing innovative treatments to help manage neurodegenerative diseases such as multiple sclerosis (MS).
As part of this commitment, we strive to develop new treatment options and drug delivery devices as well as offering enhanced patient programs and support services. In addition to our leading interferon beta therapy, Rebif®, we currently have several projects in our R&D pipeline with the potential to offer new therapeutic options to patients with MS.
 
Disclaimer

The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.